Modulation of respiratory TLR3-anti-viral response by probiotic microorganisms: Lessons learned from Lactobacillus rhamnosus CRL1505

Frontiers in Immunology

Volumn 5, Issue MAY, 2014, Pages

  Kitazawa, Haruki ^a   Villena, Julio ^b,c  

^a TOHOKU UNIVERSITY   (Japan)

^b Immunobiotics Research Group   (Argentina)

^c CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

Author keywords

Immunobiotics; Lactobacillus rhamnosus CRL1505; Respiratory immunity; Respiratory syncytial virus; TLR3

Indexed keywords

CD103 ANTIGEN; CD11 ANTIGEN; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; PATTERN RECOGNITION RECEPTOR; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIVIRAL ACTIVITY; BIFIDOBACTERIUM BREVE; CELL ACTIVATION; COXSACKIE VIRUS INFECTION; CYTOTOXICITY; GENE EXPRESSION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; INFLUENZA VIRUS A H1N1; INNATE IMMUNITY; LACTOBACILLUS CASEI; LACTOBACILLUS GASSERI; LACTOBACILLUS PENTOSUS; LACTOBACILLUS PLANTARUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; MURINE PNEUMONIA VIRUS; NATURAL KILLER CELL; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

EID: 84905509229     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00201     Document Type: Review

References (85)

1. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 162:80-99. doi: 10.1016/j.virusres.2011.09.020
2. van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol (2012) 2:300-5. doi:10.1016/j.coviro.2012.01.008
3. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 289:179-86. doi:10.1001/jama.289.2.179
4. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol (2007) 20:108-19. doi:10.1038/modpathol.3800725
5. Villena J, Salva S, Núñez M, Corzo J, Tolaba R, Faedda J, et al. Probiotics for everyone! The novel immunobiotic Lactobacillus rhamnosus CRL1505 and the beginning of Social Probiotic Programs in Argentina. Int J Biotechnol Wellness Ind (2012) 1:189-98. doi:10.6000/1927-3037/2012.01.03.05
6. Perales-Linares R, Navas-Martin S. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology (2013) 140:153-67. doi:10.1111/imm.12143
7. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem (2005) 280:5571-80. doi:10.1074/jbc.M410592200
8. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog (2006) 2:e53. doi:10.1371/journal.ppat.0020053
9. Zhang SY, Herman M, Ciancanelli MJ, Perez de Diego R, Sancho-Shimizu V, Abel L, et al. TLR3 immunity to infection in mice and humans. Curr Opin Immunol (2013) 25:19-33. doi:10.1016/j.coi.2012.11.001
10. Lotz MT, Peebles RS Jr. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr Allergy Asthma Rep (2012) 12:380-7. doi:10.1007/s11882-012-0278-z
11. Larranaga CL, Ampuero SL, Luchsinger VF, Carrion FA, Aguilar NV, Morales PR, et al. Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J (2009) 28:867-73. doi:10.1097/INF.0b013e3181a3ea71
12. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis (2007) 195:1126-36. doi:10.1086/512615
13. Welliver TP, Reed JL, Welliver RC Sr. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J (2008) 27:S92-6. doi:10.1097/INF.0b013e318168b706
14. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 171:2366-73. doi:10.4049/jimmunol.171.5.2366
15. Orange JS, Biron CA. An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J Immunol (1996) 156:1138-42.
16. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol (2010) 185:4681-90. doi:10.4049/jimmunol.1001758
17. Pribul PK, Harker J, Wang B, Wang H, Tregoning JS, Schwarze J, et al. Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J Virol (2008) 82:4441-8. doi:10.1128/JVI.02541-07
18. Kumagai Y, Takeuchi O, Kato H, Kumar H, Matsui K, Morii E, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity (2007) 27:240-52. doi:10.1016/j.immuni.2007.07.013
19. Reed JL, Brewah YA, Delaney T, Welliver T, Burwell T, Benjamin E, et al. Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis (2008) 198:1783-93. doi:10.1086/593173
20. McNamara PS, Flanagan BF, Hart CA, Smyth RL. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. J Infect Dis (2005) 191:1225-32. doi:10.1086/428855
21. Jones A, Qui JM, Bataki E, Elphick H, Ritson S, Evans GS, et al. Neutrophil survival is prolonged in the airways of healthy infants and infants with RSV bronchiolitis. Eur Respir J (2002) 20:651-7. doi:10.1183/09031936.02.00278902
22. Noah TL, Becker S. Chemokines in nasal secretions of normal adults experimentally infected with respiratory syncytial virus. Clin Immunol (2000) 97:43-9. doi:10.1006/clim.2000.4914
23. Garg R, Shrivastava P, van Drunen Littel-van den Hurk S. The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. Expert Rev Vaccines (2012) 11:1441-57. doi:10.1586/erv.12.117
24. McDermott DS, Weiss KA, Knudson CJ, Varga SM. Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection. Future Virol (2011) 6:963-73. doi:10.2217/fvl.11.62
25. Beyer M, Bartz H, Horner K, Doths S, Koerner-Rettberg C, Schwarze J. Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. J Allergy Clin Immunol (2004) 113:127-33. doi:10.1016/j.jaci.2003.10.057
26. Lukens MV, Kruijsen D, Coenjaerts FE, Kimpen JL, van Bleek GM. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. J Virol (2009) 83:7235-43. doi:10.1128/JVI.00452-09
27. Habibi MS, Openshaw PJ. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis (2012) 25:687-94. doi:10.1097/QCO.0b013e32835a1d92
28. Moore ML, Newcomb DC, Parekh VV, Van Kaer L, Collins RD, Zhou W, et al. STAT1 negatively regulates lung basophil IL-4 expression induced by respiratory syncytial virus infection. J Immunol (2009) 183:2016-26. doi:10.4049/jimmunol.0803167
29. Fischer JE, Johnson JE, Kuli-Zade RK, Johnson TR, Aung S, Parker RA, et al. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol (1997) 71:8672-7.
30. Tekkanat KK, Maassab H, Berlin AA, Lincoln PM, Evanoff HL, Kaplan MH, et al. Role of interleukin-12 and stat-4 in the regulation of airway inflammation and hyperreactivity in respiratory syncytial virus infection. Am J Pathol (2001) 159:631-8. doi:10.1016/S0002-9440(10)61734-8
31. Durbin JE, Johnson TR, Durbin RK, Mertz SE, Morotti RA, Peebles RS, et al. The role of IFN in respiratory syncytial virus pathogenesis. J Immunol (2002) 168:2944-52. doi:10.4049/jimmunol.168.6.2944
32. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol (2011) 179:248-58. doi:10.1016/j.ajpath.2011.03.003
33. Bera MM, Lu B, Martin TR, Cui S, Rhein LM, Gerard C, et al. Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins. J Immunol (2011) 187:4245-55. doi:10.4049/jimmunol.1101789
34. Sande CJ, Mutunga MN, Medley GF, Cane PA, Nokes DJ. Group- and genotype-specific neutralizing antibody responses against respiratory syncytial virus in infants and young children with severe pneumonia. J Infect Dis (2013) 207:489-92. doi:10.1093/infdis/jis700
35. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev (1995) 8:22-33.
36. Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, et al. A critical link between Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proc Natl Acad Sci U S A (2008) 105:20446-51. doi:10.1073/pnas.0810372105
37. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med (2004) 10:1366-73. doi:10.1038/nm1140
38. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol (2011) 301:L148-56. doi:10.1152/ajplung.00065.2011
39. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 26:153-62. doi:10.1002/jmv.1890260207
40. van Schaik SM, Obot N, Enhorning G, Hintz K, Gross K, Hancock GE, et al. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J Med Virol (2000) 62:257-66. doi:10.1002/1096-9071(200010)62:2<257::AID-JMV19>3.0.CO;2-M
41. Fullmer JJ, Khan AM, Elidemir O, Chiappetta C, Stark JM, Colasurdo GN. Role of cysteinyl leukotrienes in airway inflammation and responsiveness following RSV infection in BALB/c mice. Pediatr Allergy Immunol (2005) 16:593-601. doi:10.1111/j.1399-3038.2005.00248.x
42. Rutigliano JA, Graham BS. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol (2004) 173:3408-17. doi:10.4049/jimmunol.173.5.3408
43. Aeffner F, Traylor ZP, Yu EN, Davis IC. Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. Am J Physiol Lung Cell Mol Physiol (2011) 301:L99-109. doi:10.1152/ajplung.00398.2010
44. Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol (2005) 79:3350-7. doi:10.1128/JVI.79.6.3350-3357.2005
45. Rudd BD, Smit JJ, Flavell RA, Alexopoulou L, Schaller MA, Gruber A, et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol (2006) 176:1937-42. doi:10.4049/jimmunol.176.3.1937
46. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol (2006) 176:1733-40. doi:10.4049/jimmunol.176.3.1733
47. Resch B, Gusenleitner W, Mueller WD. Risk of concurrent bacterial infection in preterm infants hospitalized due to respiratory syncytial virus infection. Acta Paediatr (2007) 96:495-8. doi:10.1111/j.1651-2227.2007.00226.x
48. Villena J, Salva S, Barbieri N, Alvarez S. Immunobiotics for the prevention of bacterial and viral respiratory infections. In: Kitazawa H, Villena J, Alvarez S, editors. Probiotics: Immunobiotics and Immunogenics. Boca Raton, FL: CRC Press (2013). p. 128-68.
49. Yasui H, Kiyoshima J, Hori T, Shida K. Protection against influenza virus infection of mice fed Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol (1999) 6:186-92.
50. Hori T, Kiyoshima J, Shida K, Yasui H. Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice. Clin Diagn Lab Immunol (2001) 8:593-7. doi:10.1128/CDLI.8.3.593-597.2001
51. Hori T, Kiyoshima J, Shida K, Yasui H. Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus casei strain Shirota. Clin Diagn Lab Immunol (2002) 9:105-8. doi:10.1128/CDLI.9.1.105-108.2002
52. Yasui H, Kiyoshima J, Hori T. Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota. Clin Diagn Lab Immunol (2004) 11:675-9. doi:10.1128/CDLI.11.4.675-679.2004
53. Maeda N, Nakamura R, Hirose Y, Murosaki S, Yamamoto Y, Kase T, et al. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Int Immunopharmacol (2009) 9:1122-5. doi:10.1016/j.intimp.2009.04.015
54. Kawase M, He F, Kubota A, Harata G, Hiramatsu M. Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infection. Lett Appl Microbiol (2010) 51:6-10. doi:10.1111/j.1472-765X.2010.02849.x
55. Izumo T, Maekawa T, Ida M, Noguchi A, Kitagawa Y, Shibata H, et al. Effect of intranasal administration of Lactobacillus pentosus S-PT84 on influenza virus infection in mice. Int Immunopharmacol (2010) 10:1101-6. doi:10.1016/j.intimp.2010.06.012
56. Harata G, He F, Hiruta N, Kawase M, Kubota A, Hiramatsu M, et al. Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses. Lett Appl Microbiol (2010) 50:597-602. doi:10.1111/j.1472-765X.2010.02844.x
57. Iwabuchi N, Xiao JZ, Yaeshima T, Iwatsuki K. Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice. Biol Pharm Bull (2011) 34:1352-5. doi:10.1248/bpb.34.1352
58. Takeda S, Takeshita M, Kikuchi Y, Dashnyam B, Kawahara S, Yoshida H, et al. Efficacy of oral administration of heat-killed probiotics from Mongolian dairy products against influenza infection in mice: alleviation of influenza infection by its immunomodulatory activity through intestinal immunity. Int Immunopharmacol (2011) 11:1976-83. doi:10.1016/j.intimp.2011.08.007
59. Kobayashi N, Saito T, Uematsu T, Kishi K, Toba M, Kohda N, et al. Oral administration of heat-killed Lactobacillus pentosus strain b240 augments protection against influenza virus infection in mice. Int Immunopharmacol (2011) 11:199-203. doi:10.1016/j.intimp.2010.11.019
60. Youn HN, Lee DH, Lee YN, Park JK, Yuk SS, Yang SY, et al. Intranasal administration of live Lactobacillus species facilitates protection against influenza virus infection in mice. Antiviral Res (2012) 93:138-43. doi:10.1016/j.antiviral.2011.11.004
61. Gabryszewski SJ, Bachar O, Dyer KD, Percopo CM, Killoran KE, Domachowske JB, et al. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. J Immunol (2011) 186:1151-61. doi:10.4049/jimmunol.1001751
62. Villena J, Chiba E, Tomosada Y, Salva S, Marranzino G, Kitazawa H, et al. Orally administered Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C). BMC Immunol (2012) 13:53. doi:10.1186/1471-2172-13-53
63. Lee YN, Youn HN, Kwon JH, Lee DH, Park JK, Yuk SS, et al. Sublingual administration of Lactobacillus rhamnosus affects respiratory immune responses and facilitates protection against influenza virus infection in mice. Antiviral Res (2013) 98:284-90. doi:10.1016/j.antiviral.2013.03.013
64. Chiba E, Tomosada Y, Vizoso-Pinto MG, Salva S, Takahashi T, Tsukida K, et al. Immunobiotic Lactobacillus rhamnosus improves resistance of infant mice against respiratory syncytial virus infection. Int Immunopharmacol (2013) 17:373-82. doi:10.1016/j.intimp.2013.06.024
65. Tomosada Y, Chiba E, Zelaya H, Takahashi T, Tsukida K, Kitazawa H, et al. Nasally administered Lactobacillus rhamnosus strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC Immunol (2013) 14:40. doi:10.1186/1471-2172-14-40
66. Kechaou N, Chain F, Gratadoux JJ, Blugeon S, Bertho N, Chevalier C, et al. Identification of one novel candidate probiotic Lactobacillus plantarum strain active against influenza virus infection in mice by a large-scale screening. Appl Environ Microbiol (2013) 79:1491-9. doi:10.1128/AEM.03075-12
67. Goto H, Sagitani A, Ashida N, Kato S, Hirota T, Shinoda T, et al. Anti-influenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity. Br J Nutr (2013) 110:1810-8. doi:10.1017/S0007114513001104
68. Waki N, Yajima N, Suganuma H, Buddle BM, Luo D, Heiser A, et al. Oral administration of Lactobacillus brevis KB290 to mice alleviates clinical symptoms following influenza virus infection. Lett Appl Microbiol (2014) 58:87-93. doi:10.1111/lam.12160
69. Park MK, Ngo V, Kwon YM, Lee YT, Yoo S, Cho YH, et al. Lactobacillus plantarum DK119 as a probiotic confers protection against influenza virus by modulating innate immunity. PLoS One (2013) 8:e75368. doi:10.1371/journal.pone.0075368
70. Zelaya H, Tsukida K, Chiba E, Marranzino G, Alvarez S, Kitazawa H, et al. Immunobiotic lactobacilli reduce viral-associated pulmonary damage through the modulation of inflammation-coagulation interactions. Int Immunopharmacol (2104) 19:161-73. doi:10.1016/j.intimp.2013.12.020
71. Yasui H, Nagaoka N, Hayakawa K. Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer's patch cells with Bifidobacterium breve YIT4064. Clin Diagn Lab Immunol (1994) 1:244-6.
72. Wolf DG, Greenberg D, Kalkstein D, Shemer-Avni Y, Givon-Lavi N, Saleh N, et al. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J (2006) 25:320-4. doi:10.1097/01.inf.0000207395.80657.cf
73. Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, et al. Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Respir Res (2009) 10:43. doi:10.1186/1465-9921-10-43
74. McNamara PS, Smyth RL. The pathogenesis of respiratory syncytial virus disease in childhood. Br Med Bull (2002) 61:13-28. doi:10.1093/bmb/61.1.13
75. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med (2009) 15:277-84. doi:10.1038/nm.1929
76. Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol (2011) 187:3145-54. doi:10.4049/jimmunol.1100764
77. Loebbermann J, Schnoeller C, Thornton H, Durant L, Sweeney NP, Schuijs M, et al. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS One (2012) 7:e32371. doi:10.1371/journal.pone.0032371
78. Furuhashi K, Suda T, Hasegawa H, Suzuki Y, Hashimoto D, Enomoto N, et al. Mouse lung CD103+ and CD11bhigh dendritic cells preferentially induce distinct CD4+ T-cell responses. Am J Respir Cell Mol Biol (2012) 46:165-72. doi:10.1165/rcmb.2011-0070OC
79. Giroux M, Schmidt M, Descoteaux A. IFN-gamma-induced MHC class II expression: transactivation of class II transactivator promoter IV by IFN regulatory factor-1 is regulated by protein kinase C-alpha. J Immunol (2003) 171:4187-94. doi:10.4049/jimmunol.171.8.4187
80. Salva S, Villena J, Alvarez S. Immunomodulatory activity of Lactobacillus rhamnosus strains isolated from goat milk: impact on intestinal and respiratory infections. Int J Food Microbiol (2010) 141:82-9. doi:10.1016/j.ijfoodmicro.2010.03.013
81. Marranzino G, Villena J, Salva S, Alvarez S. Stimulation of macrophages by immunobiotic Lactobacillus strains: influence beyond the intestinal tract. Microbiol Immunol (2012) 56:771-81. doi:10.1111/j.1348-0421.2012.00495.x
82. Takanashi N, Tomosada Y, Villena J, Murata K, Takahashi T, Chiba E, et al. Advanced application of bovine intestinal epithelial cell line for evaluating regulatory effect of lactobacilli against heat-killed enterotoxigenic Escherichia coli-mediated inflammation. BMC Microbiol (2013) 13:54. doi:10.1186/1471-2180-13-54
83. Villena J, Barbieri N, Salva S, Herrera M, Alvarez S. Enhanced immune response to pneumococcal infection in malnourished mice nasally treated with heat-killed Lactobacillus casei. Microbiol Immunol (2009) 53:636-46. doi:10.1111/j.1348-0421.2009.00171.x
84. Villena J, Oliveira ML, Ferreira PC, Salva S, Alvarez S. Lactic acid bacteria in the prevention of pneumococcal respiratory infection: future opportunities and challenges. Int Immunopharmacol (2011) 11:1633-45. doi:10.1016/j.intimp.2011.06.004
85. Salva S, Nunez M, Villena J, Ramon A, Font G, Alvarez S. Development of a fermented goats' milk containing Lactobacillus rhamnosus: in vivo study of health benefits. J Sci Food Agric (2011) 91:2355-62. doi:10.1002/jsfa.4467